0.83
Nucana Plc Adr Borsa (NCNA) Ultime notizie
Stock Update - Investorsobserver
NuCana Reports Strong Phase 2 Data: 75% Disease Control in Melanoma Trial, Lower Q3 Loss - StockTitan
Get in on NuCana plc ADR’s (NCNA) buy-in window today! - SETE News
NuCana plc ADR Inc. (NCNA) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
NuCana secures new US patent for cancer treatment NUC-7738 - Investing.com India
Market Watch: NuCana plc ADR (NCNA)’s Noteworthy Drop, Closing at 3.05 - The Dwinnex
Daily Market Movement: NuCana plc ADR (NCNA) Sees a -7.03 Decrease, Closing at 3.44 - The Dwinnex
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study - Yahoo Finance
NCNA’s Financial Health: Exploring NuCana plc ADR’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle
NuCana price target lowered to $25 from $150 at Oppenheimer - TipRanks
Oppenheimer slashes NuCana stock target, remains Outperform on optimism for upcoming trials - Investing.com
NuCana Ends Phase 2 Cancer Study, Focuses on Promising Treatments - TipRanks
NuCana shares receive $150 stock PT at Oppenheimer on upbeat trial prospects - Investing.com
NuCana plc Announces Reverse ADS Split - TipRanks
NuCana: Potential Turnaround In 2024 But Risky - Seeking Alpha
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
Will NuCana Continue to Surge Higher? - Nasdaq
NuCana (NCNA) Stock Price, News & Analysis - MarketBeat
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):